Eye injection of topotecan for retinal scarring after detachment
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a medication called topotecan, which is injected into the eye during surgery to treat a serious scarring condition called proliferative vitreoretinopathy (PVR). It may help prevent the retina from detaching again after surgery for retinal detachment or eye injury.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a detached retina with significant scarring (grade C or higher) or from an eye injury
- You are scheduled for vitrectomy (a surgery to remove vitreous gel) with or without a scleral buckle
- You are not pregnant (if you are a woman of childbearing age, a pregnancy test will be done)
- You have not had silicone oil placed in your eye before this surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shot of topotecan into the eye during retinal detachment surgery to try to prevent or treat a scar-like condition called proliferative vitreoretinopathy that can cause vision loss. It is for adults who are already having surgery for a retinal tear.
This trial tests if injecting a medication called methotrexate into the eye during retinal detachment surgery can prevent scar tissue from forming. Scar tissue can sometimes cause the retina to detach again, so this treatment might lower that risk.
This trial studies a “dropless” method (fewer post-surgery eye drops) after pars plana vitrectomy, a surgery used to repair a retinal detachment. It may help by improving comfort and simplifying recovery for people having this specific type of retinal detachment repair.
This Phase 2 trial tests an injection of topotecan into the eye after surgery for retinal detachment that keeps coming back due to scar tissue (proliferative vitreoretinopathy). It may help improve how the retina heals after difficult, repeat operations when vision is usually very guarded.
This trial tests a new way to deliver the chemotherapy drug topotecan directly to the eye (via a small patch placed on the eye surface) for children with retinoblastoma that either needs eye removal or has come back after standard treatment. It aims to see if this approach can help save the eye and vision.
This trial tests a high dose of a chemotherapy drug called topotecan given directly into the eye (intravitreal injection) for children with retinoblastoma that has come back or not responded to treatment and has seeds floating in the vitreous. The goal is to save the eye when removal is the only other option.
Hear when a new Proliferative Vitreoretinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.